

**ASX: EIQ RELEASE**

**4 FEBRUARY, 2022**

## **APPOINTMENTS OF CHIEF COMMERCIAL OFFICER AND VICE PRESIDENT REGULATORY AFFAIRS**

**Sydney:** AI & Medical Technology company Echo IQ (the Company) (ASX:EIQ) is pleased to announce it has made two new additions to the Company's team. The first being the appointment of Chief Commercial Officer and the second being the appointment of Vice President Regulatory Affairs.

Incentive securities have been agreed to be issued to the parties on commencement of their employment in March 2022. The total number of securities to be issued to the parties is as follows;

- 6,000,000 Unlisted Options (Options) with an exercise price of \$0.25 and a 3 year expiry;
- 250,000 Performance Rights (Rights)

The incentive securities being issued are subject to various vesting conditions being satisfied including length of employment hurdles and sales targets. The Rights will convert to ordinary fully paid shares after 6 months of employment. An appendix 3B for the Rights will be released concurrently with this announcement.

The Options will be issued pursuant to the Company's Incentive Option Plan on commencement of employment in March and the associated appendix 3G will be released to the market at this time.

**-ENDS-**

Authorised for release by the Board of Directors of Echo IQ Limited.

**Media enquiries:**

Philip Woolff, Chief Operating Officer

[Philip.woolff@echoiq.ai](mailto:Philip.woolff@echoiq.ai) / +61 (0)490 030 620 / [marketing@echoiq.ai](mailto:marketing@echoiq.ai)

**Investor enquiries:**

Andrew Grover, Executive Chair

[Andrew.grover@echoiq.ai](mailto:Andrew.grover@echoiq.ai) / +61 (0) 481 339 512 / [Investor@HoustonWeHave.ai](mailto:Investor@HoustonWeHave.ai)